No description available.

名古屋大学博士学位論文 学位の種類 : 博士(医学)(論文) 学位授与年月日:平成5年1月28日 平山正昭氏の博士論文として提出された

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21626号 / 医博第4432号 / 新制||医||1033(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 高橋 淳, 教授 宮本 享, 教授 林 康紀 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Background: Idiopathic parkinsonism is a neurodegenerative syndrome of unknown cause and includes Parkinson’s disease (PD) and atypical parkinsonian disorders. The atypical parkinsonian disorders are: Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). The incidence rates of these diseases in Sweden are largely unknown. The diagnosis of each disease relies mainly on clinical examination although several imaging and laboratory parameters may show changes. A diagnosis based on clinical examination is especially difficult early in the course of each disease; diagnosis is easier later on when disease-charactersistic signs have evolved and become more prominent. However, even in later stages it is not uncommon that patients are misdiagnosed. PD can be divided into subgroups based on the main clinical symptoms, i. e. tremor dominant, postural instability and gait difficulty (PIGD), and indeterminate. The PIGD subtype has worse prognosis including higher risk of dementia. The aims were to study the incidence of idiopathic parkinsonism and the different specific parkinsonian disorders in the Umeåregion and to investigate the patients early in the course of the disease with brainmagnetic resonance tomography (MRI), external anal sphincterelectromyography (EAS-EMG) and oculomotor examination. Can these methods improve the differential diagnostic work-up and/or differentiate between the subtypes of PD? Methods: We examined all patients in our catchment area (142,000 inhabitants) who were referred to us due to a suspected parkinsonian syndrome. Our clinic is the only clinic in the area receiving referrals regarding movement disorders. During the period (January 1, 2004 through April 30,2009) 190 patients fulfilled the inclusion criteria and were included in the study. Healthy volunteers served as controls.  Results: Incidence: We found the highest incidences reported in the literature: PD (22.5/100,000/year), MSA(2.4/100,000/year), and PSP (1.2/100,000/year). No CBD patients were encountered. Brain MRI: Degenerative changes were common both in controls and PD. There were no differences between the PD subtypes. EAS-EMG: Pathological changes in EAS-EMG examination were common in PD, MSA and PSP. It was not possible to separate PD, MSA and PSP by the EAS-EMG examination. Oculomotor examination: Pathological results were common in all diagnosis groups compared to controls. It was not possible to separate PD, MSA and PSP or the PD subtypes with the help of oculomotor examination. Conclusions: The incidences of idiopathic parkinsonism, PD, MSA and PSP were higher than previously reported in the literature. It is not clear weather this is due to a true higher incidence in the Umeå region or a more effective casefinding than in other studies. MRI, EAS-EMG and oculomotor examination could not contribute to the differential diagnostic work-up between PD, MSA and PSP nor differentiate between PD subtypes early in the course of the disease.

nÃo hà / Este trabalho consiste de dois estudos: o primeiro estudo avalia o papel da morfometria por ressonÃncia magnÃtica (RM) no diagnÃstico diferencial das sÃndromes parkinsonianas; o segundo avalia as alteraÃÃes do sono nessas sÃndromes e suas relaÃÃes com alteraÃÃes estruturais na RM. Nas fases iniciais da doenÃa o diagnÃstico diferencial entre as sÃndromes parkinsonianas pode ser de difÃcil realizaÃÃo. As medidas por RM podem contribuir para o diagnÃstico diferencial entre a doenÃa Parkinson (DP), paralisia supranuclear progressiva (PSP) e atrofia de mÃltiplos sistemas (AMS). O objetivo do primeiro estudo foi avaliar o valor diagnÃstico das alteraÃÃes anatÃmicas estruturais identificadas pela RM no diagnÃstico diferencial dessas sÃndromes. Foram estudados 21 casos com DP, 11 casos com atrofia de mÃltiplos sistemas forma cerebelar (AMS-c), 8 casos de atrofia de mÃltiplos sistemas forma parkinsoniana (AMS-p) e 20 com PSP. A Ãrea sagital mediana do mesencÃfalo (Ams), Ãrea sagital mediana da ponte (Apn), largura mÃdia do pedÃnculo cerebelar mÃdio (PCM) e pedÃnculo cerebelar superior (PCS) foram medidas pela RM. ComparaÃÃes mÃltiplas foram realizadas entre a PD, AMS-c, AMS-p e PSP. A morfometria da Apn, PCM e PCS apresentaram diferenÃas entre os casos com diferentes diagnÃsticos. A Ams e a morfometria do PCS foram as medidas mais preditivas para o diagnÃstico de PSP, de tal forma que uma Ãrea do mesencÃfalo < 105 mm2 e a medida do PCS < 3 mm mostraram uma grande probabilidade para este diagnÃstico (sensibilidade de 95,0 e 80,0%, respectivamente). Nos casos de AMS-c, a morfometria da Apn < 315mm2 apresentou boa especificidade e valor preditivo positivo para o diagnÃstico (93,8% e 72,7%, respectivamente). Em conclusÃo, demonstramos que dimensÃes e valores de cortes obtidos a partir de exames de RM podem diferenciar entre PD, PSP e AMS-c, com boa sensibilidade, especificidade e precisÃo. Na segunda etapa desse trabalho, foram avaliados e comparados os distÃrbios do sono em pacientes com DP, AMS e PSP e as possÃveis associaÃÃes com a morfometria por RM do encÃfalo em 16 casos de DP, 13 AMS, 14 PSP e 12 controles. Os distÃrbios do sono foram avaliados pela escala de SonolÃncia de Epworth, Ãndice de Qualidade do sono de Pittsburgh (IQSP), escala de pernas inquietas e questionÃrio de Berlim. A Apn e Ams e largura do PCS e do PCM foram medidas pela RM. A mà qualidade do sono, o risco da sÃndrome da apnÃia obstrutiva do sono (SAOS) e sÃndrome das pernas inquietas (SPI) foi detectado em todos os grupos. Pacientes com AMS apresentaram maior risco de SAOS e menor nÃmero de casos com SPI. Nos casos de AMS, uma correlaÃÃo entre os escores do IQSP e o estÃgio do Hoehn & Yahr foi observada (p<0,05). Na PSP, a SPI foi freqÃente (57%) e relacionou-se com a menor duraÃÃo e pior eficiÃncia do sono. Na DP, sonolÃncia diurna excessiva relacionou-se com a atrofia do PCM (p=0,01). Em conclusÃo, o alto risco de SAOS foi comum e proeminente nos casos de AMS. SPI foi mais freqÃente na DP e na PSP. Nos casos com PSP, a SPI associou-se com uma reduÃÃo da eficiÃncia e duraÃÃo do sono; e nos pacientes com DP e sonolÃncia excessiva diurna apresentaram maior atrofia do PCM (DP com sonolÃncia excessiva diurna PCM= 16,08Â0,93; DP sem sonolÃncia excessiva diurna PCM =17,82 0,80 p=0,01), sugerindo degeneraÃÃo de estruturas do tronco cerebral nesses pacientes. / We describe two studies, as follows: one concerns the role of cerebral morphometry as evaluated by magnetic resonance imaging (MRI) in the differential diagnosis of the parkinsonian syndromes; the other is about sleep alterations and the relationship with MRI changes in these syndromes. MRI measures can be useful for differential diagnosis between Parkinson disease (PD), progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). The aim of this study was to evaluate the diagnostic value of structural anatomic changes identified by MRI in the differential diagnosis of these syndromes. We studied 21 cases with PD, 11 with MSA-c, 8 with MSA-p, 20 with PSP and 12 controls. Midbrain area (Ams), Pons area (Apn), middle cerebellar peduncle (MCP) and superior cerebellar peduncle (SCP) width were measured using MRI. Multiple comparisons were made between PD, MSA-p, MSA-c and PSP and we show that Apn, MCP and SCP width morphometry dimensions have clear cut differences in these syndromes. The Ams and SCP were the most predictive measures of PSP. A Midbrain area below 105 mm2 and SCP less than 3 mm showed a major probability for this diagnosis (sensitivity of 95.0 and 80.0%, respectively). For the group of MSA-c patients, an Apn area below 315mm2 showed good specificity and positive predictive value (93.8% and 72.7%, respectively). In conclusion, we demonstrate that dimensions and cut off values obtained from routine MRI can differentiate between PD, PSP and MSA-c with good sensitivity, specificity and accuracy. Despite common reports in PD, in other parkinsonian syndromes, sleep disturbances have been less frequently described. We compare sleep disturbances in patients with PD, MSA and PSP and analyze associations with brain MRI morphometry. This was a cross-sectional study of 16 PD cases, 13 MSA and 14 PSP. Sleep disturbances were evaluated by Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index (PSQI), Restless Legs Scale and Berlin questionnaire. Apn, Ams, MCP width, and SCP width were measured using MRI. Poor quality sleep, risk of obstructive sleep apnea (OSA) and restless legs syndrome (RLS) were detected in all groups. Patients with MSA showed higher risk of OSA and less frequent RLS. In MSA, a correlation between PSQI scores and Hoehn and Yahr stage was observed (p<0.05). In PSP, RLS was frequent (57%) and related with reduced sleep duration and efficiency. In PD, excessive daytime sleepiness was related to atrophy of the MCP (p= 0.01). High risk of OSA was common and prominent in MSA cases. RLS was more frequent in PD and PSP, and in PSP, was associated with reduced sleep efficiency and sleep duration. In conclusion, the morphometric analysis of PD patients with excessive daytime sleepiness showed more atrophy of MCP (PD with excessive daytime sleepiness MCP= 16.08Â0.93; PD without excessive daytime sleepiness MCP=17.82Â0.80 p= 0.01) suggesting widespread degeneration of brainstem sleep structures on the basis of sleep abnormalities in these patients.

京都大学 / 0048 / 新制・論文博士 / 博士(医学) / 乙第12945号 / 論医博第2097号 / 新制||医||1010(附属図書館) / 32204 / (主査)教授 髙橋 良輔, 教授 富樫 かおり, 教授 髙橋 淳 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21015号 / 医博第4361号 / 新制||医||1028(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 高橋 淳, 教授 渡邉 大, 教授 宮本 享 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 新制・課程博士 / 博士(医学) / 甲第23804号 / 医博第4850号 / 新制||医||1058(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 井上 治久, 教授 林 康紀, 教授 竹内 理 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Background: Single photon emission computed tomography (SPECT) with dopamine transporter (DAT) and dopamine D2 receptor (D2R) ligands can visualise the integrity of the nigrostriatal dopamine system. Parkinson’s disease (PD) and the atypical parkinsonian diseases (APD), progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), have similar symptoms and dopamine depletion, but differ in pharmacological response and prognosis. Clinical differentiation between PD and APD is often difficult in the early stages. The aims of the thesis were to evaluate the differential diagnostic and prognostic value of SPECT in early PD, MSA and PSP, to map the pattern of progression with dopamine SPECT, and map the pattern of dopamine SPECT in non-affected elderly volunteers with a prospective approach. Also, we evaluated the methodological aspects of dopamine SPECT with respect to image evaluation tools, reconstruction parameters and gamma cameras. Methods: 172 patients, included in an on-going clinical prospective study on idiopathic parkinsonism, participated in the SPECT study. Also, 31 age-matched healthy controls (HC) were followed within this study. SPECT was done with 123I-FP-Cit (DAT SPECT) and 123I-IBZM (D2R SPECT). Regions of interest (ROI) were used as a standard method for semi-quantitative image analysis. Results: SPECT uptake ratios from different gamma cameras could be equalised through correction equations derived from images of a brain-like phantom, provided that attenuation correction was applied. The ROI method had high reproducibility. SPECT uptake  in HC, measured with the ROI method and a volume based (VOI) method rendered similar trends, but gender and age differences in SPECT uptake were more marked with the VOI method, and less pronounced in DAT SPECT compared to D2R SPECT with both methods. The DAT SPECT uptake was significantly reduced in very early disease stage of PD and APD compared to HC. DATSPECT uptake was more reduced in PD with postural and gait disturbance (PIGD) compared to tremor-dominant PD. Decline in DAT SPECT uptake during the first year was more pronounced in PD and PSP compared to HC. D2R SPECT uptake overlapped between untreated PD and APD. After initiated treatment, the D2R SPECT uptake was significantly higher in MSA patients compared to PD, PSP and HC. Decline in D2R SPECT uptake during the first year was not significantly different between patients or compared to HC. Conclusions: 123I-FP-Cit SPECT is a valuable and sensitive method to detect early stage idiopathic parkinsonism. A different level of uptake between PIGD-PD compared to TD-PD indicates a prognostic potential. It is not possible to differ between PD, MSA and PSP in early stage with 123I-FP-Cit SPECT and no differential diagnostic value was found using 123I-IBZM SPECT in the early, untreated stage of PD, MSA and PSP. A different pattern of uptake of this ligand in MSA compared to PD and PSP during the first years of L-dopa treatment may, however, indicate a diagnostic value during the follow-up period.

L'agrégation de l'α-synucléine (α-syn) est au coeur du processus pathologique observé dans la maladie de Parkinson ou l'atrophie multi systèmatisée. La β-synucléine (β-syn) ressemble à l'α-syn mais pourrait avoir un rôle neuroprotecteur en inhibant l'agrégation de l'α- syn. Le but de cette thèse était de mettre en place et de tester chez la souris une stratégie thérapeutique visant à inhiber l'agrégation de l'α-syn en faisant exprimer la β-syn humaine via des vecteurs viraux adéno-associés (AAV). Nous avons d'abord caractérisé un modèle de synucléinopathie, la souris transgénique M83. Ces souris expriment l'α-syn humaine mutée en A53T, et développent une pathologie sévère associée à l'agrégation de l'α-syn. Nos résultats confirment le fait que l'agrégation de l'α-syn peut se propager à partir de l'injection périphérique de forme agrégée de la protéine, vers le système nerveux central. De plus, ils montrent que l'accumulation de l'α-syn pathologique chez la souris M83 malade dépend de l'inoculum utilisé pour accélérer leur pathologie et du niveau d'expression de l'α-syn mutée en A53T chez ces souris. Les essais de thérapie génique réalisés dans ce modèle M83 suggèrent que, quelle que soit la stratégie d'injection du vecteur AAV utilisée, la β-syn n'a pas eu d'effet protecteur détecté contre l'agrégation de l'α-syn. Une expression durable de la protéine β-syn humaine chez les souris M83 malades inoculées avec le vecteur AAV véhiculant le gène de la β-syn a pourtant été confirmée. Cependant, la β-syn pourrait s'être agrégée dans nos conditions expérimentales, comme cela a été précédemment décrit, ce qui pourrait peut-être expliquer l'absence d'effet protecteur détecté / The aggregation of α-synuclein (α-syn) is central in the pathological process observed in Parkinson’s disease or multiple system atrophy. Β synuclein (β-syn) shares some similarities with α-syn but may have a neuroprotective effect by inhibiting the aggregation of α-syn. The goal of this thesis was to develop and to test a therapeutical strategy potentially able to inhibit the aggregation of α-syn by expressing human β-syn using adeno-associated vectors (AAV). First, we characterized a model of synucleinopathy, the M83 transgenic mouse. These mice express the human A53T mutated α-syn and develop a severe disease associated with the aggregation of α-syn. Our results confirm the ability of the aggregation of α-syn to spread through the central nervous system following a peripheral injection of aggregates of α-syn. Furthermore, they show that the accumulation of pathological α-syn in sick M83 mice depends on the inoculum used to accelerate their disease and the expression level of human A53T mutated α-syn in these mice. Gene therapy trials realized in the M83 model suggest that, regardless the strategy used to inject AAV vector, β syn did not have a protective effect against the aggregation of α-syn. A lasting expression of the human β-syn protein was however detected in sick M83 mice injected with AAV vector carrying human β-syn gene. Nevertheless, β-syn could have aggregated in our specific experimental conditions, as this has already been described, which might explain the absence of protective effect detected